by Mike Bassett
— Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy
The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the
… Read moreby Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
by Jordyn Sava
In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.
Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more
A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more
by Victoria Johnson
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including
… Read moreby Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more
CCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
by Charles Bankhead
Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed.
Two-year postoperative survival … Read more
In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.
Interim data from a … Read more
by Vicki Moore, PhD
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured. The team detailed their findings in Gynecologic Oncology.
To determine what … Read more
by Brittany Lovely
Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates (ADCs) represent a promising development for this population.1
The treatment landscape for patients who experience disease progression
by Emily Henderson, B.Sc.
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that cancer turns the body’s defenses against itself. However, new research from Nagoya University published in Matrix Biology suggests … Read more
by Jason Harris
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.1
Increasing the racial and ethnic diversity in
… Read moreby Caroline Seymour
The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the … Read more
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
by Brielle Benyon
Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.
The Food and Drug Administration (FDA) approved Tafinlar
by Chris Ryan
The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in
by Caroline Seymour
The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.
The combination
